NCT01380106View on ClinicalTrials.gov

Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

September 11, 2017

Study Completion Date

September 11, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Lenalidomide 15mg

Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.

DRUG

Lenalidomide 25mg

Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle

Trial Locations (7)

15240

Pittsburgh VA Medical Center, Pittsburgh

60141

Edward Hines Jr VA Hospital, Hines

64128

Kansas City VA Medical Center, Kansas City

72205

Central Arkansas Veterans Healthcare System, Little Rock

77030

Houston VA Medical Center, Houston

90073

West Los Angeles VA Medical Center, Los Angeles

02130

VA Boston Healthcare System, Jamaica Plain

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

collaborator

Kansas City Veteran Affairs Medical Center

FED

collaborator

VA Pittsburgh Healthcare System

FED

collaborator

VA Greater Los Angeles Healthcare System

FED

collaborator

Michael E. DeBakey VA Medical Center

FED

collaborator

Edward Hines Jr. VA Hospital

FED

lead

Boston VA Research Institute, Inc.

OTHER